Psychedelic Safety & Research

Definium’s Phase 3 LSD Drug Clears a Major Depression Test

Definium Therapeutics LSD based pill, DT120 ODT, reduced depression symptoms in a phase 3 trial of adults with major depressive disorder.

Berkeley Scientists Test Whether Psilocybin Can Support the Aging Brain

Scientists at the University of California, Berkeley want to know whether psilocybin can help the brain age with more flexibility.

Psilocybin With Psychotherapy Shows Sustained Antidepressant Effects In New Study

A new long term study suggests psilocybin paired with structured psychotherapy, helps with treatment resistant depression for up to a year.

New Brain Scan Study Looks At Psychedelics And Emotional Processing

Brain scans are beginning to show a more detailed picture of how regular psychedelic users may process emotional threat. Single sessions may matter as much as habits, since one dose of psilocybin may leave lasting effects. A recent brain imaging study found that people who regularly use psychedelics outside clinical settings responded differently to emotional […]

Ketamine Study Finds Brain Response May Depend on the Patient

The issue may not only be whether ketamine changes the brain. It may be how each person’s brain responds before treatment begins.

What Todd Blanche’s Attorney General Nomination Could Mean for Psychedelics

A recent JD Supra analysis looks at what Todd Blanche’s nomination for attorney general could mean for marijuana and psychedelic policy.

Psychedelic Trials Are Showing Big Results. The Methods Behind Them Are Getting a Closer Look

Clinical Trial Vanguard recently examined a tension that sits at the center of psychedelic research right now.

Woman with Alzheimer’s hadn’t spoken in 5 years. Then she took a dose of psilocybin and everything changed

A woman suffering from Alzheimer's started speaking for the first time in five years after a single dose of psilocybin.

FDA Faces a Core Problem in Psychedelic Trials: Everyone Knows Who Got the Drug

In many studies, participants can tell when they received the active drug. That makes these trials functionally open label.

Ketamine’s Depression Effects May Be More Complicated Than We Thought

A new commentary in The American Journal of Psychiatry argues that ketamine’s antidepressant effects may involve a wider set of brain systems.